Editas Medicine Inc (EDIT)
2.67
-0.10
(-3.61%)
USD |
NASDAQ |
Nov 15, 11:45
Editas Medicine Free Cash Flow (Quarterly): -55.51M for Sept. 30, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | -55.51M |
June 30, 2024 | -60.56M |
March 31, 2024 | -51.74M |
December 31, 2023 | -23.55M |
September 30, 2023 | -35.70M |
June 30, 2023 | -40.04M |
March 31, 2023 | -37.61M |
December 31, 2022 | -42.90M |
September 30, 2022 | -48.62M |
June 30, 2022 | -38.48M |
March 31, 2022 | -51.48M |
December 31, 2021 | -37.43M |
September 30, 2021 | -43.13M |
June 30, 2021 | -41.66M |
March 31, 2021 | -49.56M |
December 31, 2020 | -41.48M |
September 30, 2020 | -56.59M |
June 30, 2020 | -32.70M |
March 31, 2020 | -56.24M |
December 31, 2019 | 39.33M |
Date | Value |
---|---|
September 30, 2019 | -29.13M |
June 30, 2019 | -27.32M |
March 31, 2019 | -29.72M |
December 31, 2018 | -0.088M |
September 30, 2018 | -8.779M |
June 30, 2018 | -18.12M |
March 31, 2018 | -23.47M |
December 31, 2017 | -25.36M |
September 30, 2017 | -28.73M |
June 30, 2017 | -26.52M |
March 31, 2017 | 69.14M |
December 31, 2016 | -14.35M |
September 30, 2016 | -17.75M |
June 30, 2016 | -11.06M |
March 31, 2016 | -10.57M |
December 31, 2015 | -8.409M |
September 30, 2015 | -12.13M |
June 30, 2015 | 19.91M |
March 31, 2015 | -6.248M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-60.56M
Minimum
Jun 2024
39.33M
Maximum
Dec 2019
-40.28M
Average
-42.28M
Median
Free Cash Flow (Quarterly) Benchmarks
EyePoint Pharmaceuticals Inc | -40.60M |
Cassava Sciences Inc | -18.31M |
Adverum Biotechnologies Inc | -21.34M |
Regenxbio Inc | -40.88M |
Apellis Pharmaceuticals Inc | 34.10M |